Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Interim 2017/18 influenza seasonal vaccine effectiveness. Combined results from five European studies / Rondy, M; Kissling, E; Emborg, Hd; Gherasim, A; Pebody, R; Trebbien, R; Pozo, F; Larrauri, A; Mcmenamin, J; Valenciano, M; Kaic, B; Kurecic Filipovic, S; Visekruna-Vucina, V; Pem Novosel, I; Lovric, Z; Petrović, G; Krause, Tg; Fischer, Tk; Lina, B; Falchi, Antonella; Vilcu, Am; Souty, C; Blanchon, T; van der Werf, S; Enouf, V; Behillil, S; Valette, M; Bernard-Stoecklin, S; Lévy-Bruhl, D; Launay, O; Loulergue, P; Lenzi, N; Lesieur, Z; L'Honneur, As; Galtier, F; Agostini, C; Serrand, C; Merle, C; Foulongne, V; Vanhems, P; Lainé, F; Lagathu, G; Carrat, F; Buda, S; Preuss, U; Prahm, K; Schweiger, B; Wedde, M; Heider, A; Martin, M; Biere, B; Duerrwald, R; Domegan, L; Coughlan, L; O’Donnell, J; Joyce, M; Collins, C; Dunford, L; Moran, J; Tuite, G; Duffy, M; Connell, J; de Gascun, C; Rizzo, C; Bella, A; Alfonsi, V; Castrucci, Mr; Puzelli, S; Pagani, E; Ghisetti, V; Pariani, E; Baldanti, F; Palù, G; D'Agaro, P; Ansaldi, F; Affanni, P; Rossolini, Gm; Camilloni, B; Bagnarelli, P; Sanguinetti, M; Atripaldi, L; Chironna, M; Serra, C; Vitale, F; Chironna, M; Germinario, C; Orsi, A; Ansaldi, F; Manini, I; Montomoli, E; Napoli, C; Orsi, Gb; Casado, I; Castilla, J; Fernandino, L; Martínez-Baz, I; Ezpeleta, G; Navascués, A; Pérez-García, A; Aguinaga, A; Ezpeleta, C; Meijer, A; van den Brink, S; van der Hoek, W; Goderski, G; Wijsman, L; Bagheri, M; Dijkstra, F; de Lange, M; Marzec, T; Overduin, P; Teirlinck, A; Wentink, E; Donker, G; Marbus, S; van Gageldonk- Lafeber, R; Schneeberger, P; van Oosterheert, Jj; Schweitzer, V; Groeneveld, G; Nunes, B; Machado, A; Rodrigues, Ap; Gomez, V; Kislaya, I; Guiomar, R; Pechirra, P; Cristóvão, P; Costa, I; Panarra, A; Côrte-Real, R; Poças, J; João Peres, M; Larrauri, A; Gherasim, A; Pozo, F; García Comas, L; Marisquerena, Mei; Galán, Jc; Folgueira, D; Gonzalez Carril, F; Sancho Martínez, R; Cilla, G; Castilla, J; García Cenoz, M; Navascués, A; Quiñones Rubio, C; Martinez Ochoa, E; Blasco, M; Gimenez Duran, J; Vanrell, Jm; Reina, J; Castrillejo, D; Larrauri, A; Gherasim, Am; Delgado, C; Oliva, J; Casas, I; Larrauri, A; Gherasim, Am; Pozo, F; Casas, I; García, M; Latorre, M; Milagro Beamonte, Am; Martinez Sapiñ, A; Oribe Amores, M; Aizpurúa, A; Cilla, G; Montes, M; Zakikhany, K; Brytting, M; Wiman, Å; Carnahan, A; Pebody, R; Warburton, F; Djennad, A; Ellis, J; Andrews, N; Marques, D; Cottrell, S; Reynolds, A; Gunson, R; Galiano, M; Lackenby, A; Robertson, C; O’Doherty, M; Sinnathamby, M; Yonova, I; Moore, C; Sartaj, M; de Lusignan, S; Mcmenamin, J; Zambon, M; Valenciano, M; Moren, A; Kissling, E; Rondy, M; Penttinen, P.. - In: EUROSURVEILLANCE. - ISSN 1560-7917. - 23:9(2018), pp. 1-12. [10.2807/1560-7917.ES.2018.23.9.18-00086]
Interim 2017/18 influenza seasonal vaccine effectiveness. Combined results from five European studies
FALCHI, Antonella;Martin M;Martin Moran, Josè Manuel;Napoli CMembro del Collaboration Group
;Orsi GB;RIBEIRO MACHADO, CARLOS AUGUSTO;DIAZ GOMEZ, MARIA VANESSA;MONTES, MARCO;Ellis J;REYNOLDS, ALEXANDER;Galiano M;
2018
Abstract
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.File | Dimensione | Formato | |
---|---|---|---|
Rondy_Interim_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
531.85 kB
Formato
Adobe PDF
|
531.85 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.